QUVIVIQ (Daridorexant): Uses, Dosage & Side Effects
A dual orexin receptor antagonist for the treatment of insomnia in adults
Quick Facts About QUVIVIQ
Key Takeaways About QUVIVIQ
- New mechanism of action: QUVIVIQ blocks orexin wake-signalling rather than sedating the brain through GABA receptors, offering a fundamentally different approach to treating insomnia
- Improves daytime function: Clinical trials demonstrated that QUVIVIQ 50 mg significantly improved next-day functioning, a benefit not consistently seen with older sleep medications
- Low abuse potential: Unlike benzodiazepines and Z-drugs, QUVIVIQ is not classified as a controlled substance in the EU and shows low dependence liability
- Can be stopped without tapering: QUVIVIQ can be discontinued without gradual dose reduction and without significant rebound insomnia
- Avoid strong CYP3A4 inhibitors: Do not take QUVIVIQ with certain antifungal, antibiotic, or HIV medications that strongly inhibit the CYP3A4 enzyme
What Is QUVIVIQ and What Is It Used For?
QUVIVIQ (daridorexant) is a dual orexin receptor antagonist (DORA) prescribed for the treatment of insomnia in adults. It works by blocking orexin neuropeptides in the brain that promote wakefulness, helping you fall asleep faster and stay asleep longer without the broad sedation caused by traditional sleeping pills.
QUVIVIQ contains the active substance daridorexant, which belongs to a relatively new class of medications known as orexin receptor blockers or dual orexin receptor antagonists (DORAs). Orexin (also known as hypocretin) is a neuropeptide produced in the lateral hypothalamus of the brain. The orexin system plays a central role in maintaining wakefulness and regulating the sleep-wake cycle. In healthy individuals, orexin levels naturally rise during the day to promote alertness and decline at night to facilitate sleep.
Daridorexant works by competitively binding to both orexin-1 (OX1R) and orexin-2 (OX2R) receptors, thereby blocking the wake-promoting effects of orexin-A and orexin-B. This mechanism is fundamentally different from traditional hypnotics such as benzodiazepines (e.g. diazepam) and Z-drugs (e.g. zopiclone), which work by enhancing the inhibitory neurotransmitter GABA. By specifically targeting the wake-promotion system rather than broadly depressing central nervous system activity, QUVIVIQ allows for a more physiological transition to sleep.
QUVIVIQ was developed by Idorsia Pharmaceuticals and received marketing authorisation from the European Medicines Agency (EMA) in 2022. In the United States, the FDA approved daridorexant under the same brand name in January 2022. It is the newest member of the DORA class, following suvorexant (Belsomra) and lemborexant (Dayvigo). Compared to its predecessors, daridorexant was designed to have a shorter duration of action (terminal half-life of approximately 8 hours), which helps reduce next-morning residual effects while still providing sufficient sleep maintenance throughout the night.
The approval of QUVIVIQ was based on pivotal Phase 3 clinical trials, including the landmark studies published in The Lancet Neurology. These trials demonstrated that daridorexant 50 mg significantly improved objective and subjective measures of sleep onset and sleep maintenance in adults with insomnia disorder, and importantly, also improved self-reported daytime functioning — a measure that many older hypnotics have failed to consistently improve.
QUVIVIQ is intended to treat insomnia characterised by difficulty falling asleep (sleep-onset insomnia) and/or staying asleep (sleep-maintenance insomnia). It is not a general sedative and does not have the muscle-relaxant or anti-anxiety properties of benzodiazepines. Before prescribing QUVIVIQ, your healthcare provider should assess and address any underlying causes of your sleep difficulties, such as depression, anxiety, chronic pain, or sleep apnoea.
What Should You Know Before Taking QUVIVIQ?
QUVIVIQ is not suitable for everyone. You must not take it if you have narcolepsy or if you are taking strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, or ritonavir. Special caution is needed if you have depression, liver problems, respiratory conditions, or are over 65 years of age.
Contraindications
You must not take QUVIVIQ if any of the following applies to you:
- Allergy to daridorexant or any of the other ingredients in QUVIVIQ (including mannitol, microcrystalline cellulose, povidone, croscarmellose sodium, colloidal silicon dioxide, or magnesium stearate)
- Narcolepsy: A condition characterised by sudden and uncontrollable episodes of sleep. Since QUVIVIQ blocks orexin receptors — the same system that is deficient in narcolepsy — using it in narcolepsy patients would worsen their condition
- Concurrent use of strong CYP3A4 inhibitors: These medications significantly increase daridorexant blood levels and include:
- Oral antifungal agents: ketoconazole, posaconazole, voriconazole, itraconazole
- Certain antibiotics: clarithromycin, josamycin, telithromycin, troleandomycin
- Certain HIV medications: ritonavir, elvitegravir, indinavir, saquinavir, lopinavir, nelfinavir, boceprevir
- Certain cancer medications: ceritinib, idelalisib, ribociclib, tucatinib
If you are unsure whether a medication you are taking might interact with QUVIVIQ, always consult your healthcare provider or pharmacist before starting treatment.
Warnings and Precautions
Talk to your healthcare provider before taking QUVIVIQ if you have or have had any of the following:
- Depression or suicidal thoughts: QUVIVIQ should be used with caution in patients with depression. If you are depressed and notice your condition worsening, or if you have thoughts of self-harm, contact your doctor immediately
- Psychiatric illness: Any current psychiatric disorder requires careful evaluation before starting QUVIVIQ
- Concurrent CNS-active medications: If you are currently taking medications that affect the brain, such as treatments for anxiety or depression, the combined effects with QUVIVIQ need to be carefully considered
- History of substance abuse: Patients with a history of drug or alcohol dependence may be at higher risk and should be closely monitored
- Liver problems: Depending on the severity of hepatic impairment, QUVIVIQ may not be recommended or a lower dose (25 mg) may be necessary. Daridorexant is primarily metabolised in the liver by CYP3A4
- Respiratory difficulties: Patients with severe chronic obstructive pulmonary disease (COPD) should use QUVIVIQ with caution
- Fall risk in elderly patients: If you are over 65 years of age and have a history of falls, QUVIVIQ should be used with particular caution, as there is a higher risk of falls in this population
QUVIVIQ may cause sleep paralysis (a temporary inability to move or speak for up to several minutes when falling asleep or waking up) and hallucinations (vivid or frightening visual or auditory experiences that are not real). These are uncommon side effects related to the orexin-blocking mechanism. If you experience these symptoms, inform your healthcare provider, who may adjust your treatment.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your healthcare provider before taking QUVIVIQ. The safety of QUVIVIQ during pregnancy has not been established in humans. It is not known whether daridorexant can harm the developing foetus, so it should only be used during pregnancy if the potential benefit justifies the potential risk.
A small amount of daridorexant passes into breast milk. If you are breastfeeding, talk to your doctor about the best way to feed your baby during treatment with QUVIVIQ. Your healthcare provider will help you weigh the benefits of breastfeeding against the potential effects of the medication on your infant.
The effects of QUVIVIQ on human fertility are not known. Preclinical studies in animals did not indicate harmful effects on reproductive function, but human data are limited.
Children and Adolescents
QUVIVIQ is not intended for use in children and adolescents under 18 years of age. Daridorexant has not been studied in this age group, and its safety and efficacy have not been established. For young people with sleep difficulties, non-pharmacological interventions such as sleep hygiene education, cognitive behavioural therapy, and behavioural strategies are recommended as first-line approaches.
Driving and Operating Machinery
QUVIVIQ may affect your ability to drive and operate machinery. It is recommended to wait approximately 9 hours after taking QUVIVIQ before driving or using machines. Be particularly cautious in the morning after taking the medication, especially during the first few days of treatment. Do not engage in activities that could be dangerous if you are not fully alert, particularly shortly after waking.
QUVIVIQ can be taken with or without food, but taking it with or shortly after a large meal may delay onset of action. Avoid alcohol while taking QUVIVIQ, as alcohol can increase the risk of balance problems and coordination difficulties. You should also avoid grapefruit and grapefruit juice in the evening, as these can increase the level of QUVIVIQ in your blood by inhibiting CYP3A4.
How Does QUVIVIQ Interact with Other Drugs?
QUVIVIQ is metabolised by the liver enzyme CYP3A4 and interacts significantly with drugs that inhibit or induce this enzyme. Strong CYP3A4 inhibitors are contraindicated. CNS depressants including benzodiazepines and alcohol can enhance the sedative effects of QUVIVIQ and should be used with caution.
Daridorexant is primarily metabolised by the cytochrome P450 enzyme CYP3A4. This means that drugs which strongly inhibit or induce CYP3A4 can substantially alter the blood levels of QUVIVIQ, either increasing the risk of side effects or reducing its therapeutic efficacy. Additionally, QUVIVIQ can itself affect the metabolism of certain other drugs by inhibiting P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP) transporters at intestinal level.
Contraindicated Combinations
The following medications must not be taken together with QUVIVIQ:
| Drug / Drug Class | Mechanism | Clinical Consequence |
|---|---|---|
| Ketoconazole, itraconazole, posaconazole, voriconazole (azole antifungals) | Strong CYP3A4 inhibition significantly increases daridorexant exposure | Excessive sedation and increased risk of all side effects. Use is contraindicated. |
| Clarithromycin, josamycin, telithromycin (macrolide antibiotics) | Strong CYP3A4 inhibition increases daridorexant plasma levels | Risk of profound sedation. Combination is contraindicated. |
| Ritonavir, lopinavir, indinavir, saquinavir, nelfinavir (HIV protease inhibitors) | Strong CYP3A4 inhibition increases daridorexant exposure | Excessive drug levels and toxicity risk. Use is contraindicated. |
| Ceritinib, idelalisib, ribociclib, tucatinib (cancer medications) | Strong CYP3A4 inhibition increases daridorexant levels | Unpredictable increase in drug effects. Combination is contraindicated. |
Significant Interactions Requiring Caution
The following drug interactions may require dose adjustments or careful monitoring by your healthcare provider:
| Drug / Drug Class | Effect on QUVIVIQ | Clinical Advice |
|---|---|---|
| Erythromycin, ciprofloxacin (moderate CYP3A4 inhibitors) | Moderate increase in daridorexant blood levels | Monitor for increased sedation. Dose reduction to 25 mg may be considered. |
| Cyclosporine (immunosuppressant) | Moderate CYP3A4 inhibition increases daridorexant levels | Use with caution. Your doctor will advise on appropriate dosing. |
| Rifampicin (antibiotic / CYP3A4 inducer) | Strong CYP3A4 induction significantly reduces daridorexant levels | QUVIVIQ may become ineffective. Alternative insomnia treatment may be needed. |
| Efavirenz (HIV medication / CYP3A4 inducer) | Moderate CYP3A4 induction reduces daridorexant levels | Reduced efficacy expected. Discuss alternatives with your doctor. |
| Diazepam, alprazolam (benzodiazepines / CNS depressants) | Additive sedation and CNS depression | Increased risk of excessive drowsiness and impaired coordination. Use lowest effective doses. |
| Dabigatran (anticoagulant) | QUVIVIQ may increase dabigatran levels via P-gp inhibition | Monitor for signs of bleeding. Your doctor may need to adjust the anticoagulant dose. |
| Digoxin (heart medication) | QUVIVIQ may increase digoxin levels via P-gp inhibition | Monitor digoxin blood levels and watch for signs of toxicity. |
What Is the Correct Dosage of QUVIVIQ?
The recommended dose of QUVIVIQ for most adults is 50 mg taken once in the evening, approximately 30 minutes before bedtime. A lower dose of 25 mg may be prescribed for patients with liver impairment or those taking certain other medications. QUVIVIQ should always be taken exactly as prescribed by your healthcare provider.
Adults
Standard Adult Dose
The recommended dose is one 50 mg tablet taken once per evening, approximately 30 minutes before going to bed. Swallow the tablet whole with water. QUVIVIQ can be taken with or without food, but a large meal shortly before taking the tablet may delay its onset of action.
Reduced Dose (25 mg)
A lower dose of 25 mg once per evening may be prescribed if you:
- Have moderate liver impairment (hepatic impairment)
- Are taking certain other medications that moderately increase QUVIVIQ blood levels (moderate CYP3A4 inhibitors)
QUVIVIQ is not recommended for patients with severe liver impairment.
| Patient Group | Recommended Dose | Notes |
|---|---|---|
| Adults (18-64 years) | 50 mg once daily | Take 30 minutes before bedtime |
| Elderly (65+ years) | 50 mg once daily | No dose adjustment needed; monitor for fall risk |
| Moderate liver impairment | 25 mg once daily | Reduced metabolism; lower dose required |
| Severe liver impairment | Not recommended | Insufficient data on safety |
| Moderate CYP3A4 inhibitor use | 25 mg once daily | Drug interaction increases QUVIVIQ levels |
| Children (<18 years) | Not recommended | Safety and efficacy not established |
Treatment Duration
The treatment duration should be as short as possible. The suitability of continued treatment should be evaluated within 3 months and at regular intervals thereafter. Your healthcare provider will assess whether QUVIVIQ remains appropriate for you based on your sleep quality and any side effects experienced. Clinical trials have studied daridorexant for up to 12 months, demonstrating sustained efficacy without the development of tolerance.
Missed Dose
If you forget to take QUVIVIQ at bedtime, do not take it later during the night. Taking it too late could cause you to feel drowsy the following morning, impairing your ability to drive and carry out daily activities. Do not take a double dose to compensate for a forgotten tablet. Simply take your next dose at the usual time the following evening.
Overdose
If you have taken more QUVIVIQ than prescribed, you may experience excessive drowsiness and muscle weakness. There is no specific antidote for daridorexant overdose. Contact your healthcare provider or poison control centre immediately. Treatment is supportive and may include monitoring of vital signs and observation until symptoms resolve.
QUVIVIQ contains less than 1 mmol sodium (23 mg) per tablet, making it essentially sodium-free. This is relevant for patients on a controlled sodium diet. The tablet should be swallowed whole and not crushed, chewed, or broken.
What Are the Side Effects of QUVIVIQ?
Like all medicines, QUVIVIQ can cause side effects, although not everyone experiences them. The most commonly reported side effects are headache, drowsiness, dizziness, fatigue, and nausea. Uncommon but noteworthy side effects include sleep paralysis, hallucinations, and sleepwalking. QUVIVIQ generally has a favourable side effect profile compared to traditional hypnotics.
The side effect profile of QUVIVIQ reflects its targeted mechanism of action on orexin receptors. Clinical trials involving thousands of patients demonstrated that QUVIVIQ is generally well tolerated, with most adverse effects being mild to moderate in severity. The overall incidence of side effects with QUVIVIQ 50 mg was similar to placebo in many categories, which is a notable difference compared to the more broadly-acting traditional hypnotics.
The following side effects have been observed in clinical trials and post-marketing experience:
Common
- Headache — the most frequently reported side effect, usually mild and transient
- Somnolence (excessive drowsiness) — may persist into the morning, particularly during the first days of treatment
- Dizziness — typically mild and resolves with continued treatment
- Fatigue — feeling of tiredness or lack of energy, usually mild
- Nausea — feeling of sickness, generally transient
Uncommon
- Sleep paralysis — a temporary inability to move or speak lasting up to several minutes when falling asleep or waking up. This is a known effect related to orexin receptor blockade and is generally harmless, though it can be frightening
- Hallucinations — vivid or frightening visual or auditory perceptions that are not real, occurring while falling asleep (hypnagogic) or waking up (hypnopompic)
- Allergic reactions — including skin rash and urticaria (hives). Seek medical attention if you develop signs of a severe allergic reaction
- Abnormal dreams or nightmares — unusually vivid, strange, or distressing dreams
- Sleepwalking (somnambulism) — performing activities while not fully awake, with no memory of the events. Report any episodes to your doctor immediately
It is important to note that unlike traditional hypnotics such as benzodiazepines and Z-drugs, QUVIVIQ has not been associated with significant tolerance (loss of effect over time), physical dependence, or rebound insomnia upon discontinuation in clinical trials. The Phase 3 studies showed that patients who stopped taking QUVIVIQ did not experience withdrawal symptoms or a worsening of insomnia beyond their pre-treatment baseline.
Contact your healthcare provider immediately if you experience worsening depression or thoughts of self-harm while taking QUVIVIQ. Also seek medical attention if you develop signs of a severe allergic reaction (difficulty breathing, swelling of the face or throat, severe rash) or if you engage in complex sleep behaviours such as sleepwalking or sleep-driving.
If you experience any side effects, including any not listed above, talk to your healthcare provider or pharmacist. Reporting suspected adverse reactions helps enable continued monitoring of the benefit-risk balance of the medication.
How Should You Store QUVIVIQ?
Store QUVIVIQ at room temperature, out of the sight and reach of children. No special storage conditions are required. Do not use after the expiry date printed on the packaging.
Keep QUVIVIQ out of the sight and reach of children at all times. Check the expiry date on the carton and blister pack before taking the medication — the expiry date refers to the last day of the stated month.
QUVIVIQ does not require any special storage conditions. Store the tablets in their original blister packaging to protect them from moisture and light. There is no need for refrigeration.
Do not dispose of medicines via wastewater or household waste. Return any unused or expired QUVIVIQ tablets to your pharmacist for safe disposal. Proper medication disposal helps protect the environment and prevents accidental ingestion by others.
What Does QUVIVIQ Contain?
QUVIVIQ contains the active substance daridorexant (as daridorexant hydrochloride). The 25 mg tablets are light purple and triangular, while the 50 mg tablets are light orange and triangular. Both strengths are available in blister packs of 10, 20, or 30 tablets.
Active Substance
Each QUVIVIQ tablet contains daridorexant hydrochloride equivalent to either 25 mg or 50 mg of daridorexant. Daridorexant hydrochloride is the salt form of the active molecule, which is used to improve the stability and absorption of the drug.
Inactive Ingredients
The complete list of excipients in QUVIVIQ is as follows:
- Tablet core: Mannitol (E421), microcrystalline cellulose (E460), povidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate
- Film coating: Hypromellos (E464), microcrystalline cellulose (E460), glycerol, talc (E553), titanium dioxide (E171), red iron oxide (E172), black iron oxide (E172), yellow iron oxide (E172 — 50 mg tablets only)
QUVIVIQ contains less than 1 mmol sodium (23 mg) per tablet, meaning it is essentially sodium-free. The croscarmellose sodium content is minimal and clinically insignificant even for patients on strict low-sodium diets.
Tablet Appearance
- QUVIVIQ 25 mg: Light purple, triangular film-coated tablet with “25” on one side and “i” (the Idorsia logo) on the other side
- QUVIVIQ 50 mg: Light orange, triangular film-coated tablet with “50” on one side and “i” (the Idorsia logo) on the other side
QUVIVIQ is supplied in blister packs containing 10, 20, or 30 film-coated tablets. Not all pack sizes may be marketed in all countries. The marketing authorisation holder is Idorsia Pharmaceuticals Deutschland GmbH, based in Lörrach, Germany.
Frequently Asked Questions About QUVIVIQ
QUVIVIQ (daridorexant) works by a fundamentally different mechanism compared to traditional sleeping pills like benzodiazepines or Z-drugs (zopiclone, zolpidem). Instead of enhancing the sedative GABA system, QUVIVIQ blocks orexin receptors in the brain that promote wakefulness. This targeted approach means it helps you fall asleep by turning down the wake signal rather than forcing sedation. Clinical studies suggest this results in a lower risk of next-day drowsiness, less abuse potential, and a more favourable dependence profile. Importantly, QUVIVIQ has been shown to improve daytime functioning, which traditional hypnotics have often failed to demonstrate.
In clinical trials, QUVIVIQ showed a low potential for abuse and dependence compared to traditional hypnotic medications. It is not classified as a controlled substance in the European Union. However, as with any sleep medication, it should be used as directed by your healthcare provider, and the need for continued treatment should be reassessed regularly, typically within 3 months and periodically thereafter. If you have a history of substance abuse, discuss this with your doctor before starting QUVIVIQ.
Yes, QUVIVIQ can be taken with or without food. However, taking it with or shortly after a large meal may delay its onset of action. For optimal results, take the tablet approximately 30 minutes before bedtime. Important: avoid grapefruit or grapefruit juice in the evening, as these can increase QUVIVIQ blood levels by inhibiting CYP3A4 enzymes. You must also avoid alcohol, as it can enhance the sedative effects and increase the risk of balance problems.
If you forget to take QUVIVIQ at bedtime, do not take it later during the night, as this could cause excessive morning drowsiness and impair your ability to drive or perform daily activities safely. Simply skip the missed dose and take your next dose at the usual time the following evening. Never take a double dose to make up for a forgotten tablet.
Yes, unlike many traditional sleeping pills such as benzodiazepines and Z-drugs, QUVIVIQ can be stopped without the need for gradual dose reduction. Clinical studies have not shown significant withdrawal effects or rebound insomnia after discontinuing treatment. This is one of the key advantages of the orexin receptor antagonist mechanism. However, it is always advisable to discuss any changes to your medication regimen with your healthcare provider before stopping treatment.
QUVIVIQ reaches peak blood concentration in approximately 1 to 2 hours after ingestion. Clinical trials showed significant improvements in sleep onset from the first night of treatment. For best results, take the tablet about 30 minutes before you intend to go to sleep, and ensure you have enough time for a full night of sleep (at least 7 hours). Avoid taking the tablet with a heavy meal, as this may delay absorption.
References
- European Medicines Agency (EMA). QUVIVIQ (daridorexant) — Summary of Product Characteristics (SmPC). Last updated 2024.
- Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. The Lancet Neurology. 2022;21(2):125-139.
- U.S. Food and Drug Administration (FDA). QUVIVIQ (daridorexant) Prescribing Information. January 2022.
- Kunz D, Dauvilliers Y, Benes H, et al. Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs. 2023;37(1):93-106.
- World Health Organization (WHO). ATC/DDD Index 2024. Anatomical Therapeutic Chemical classification of daridorexant.
- Muehlan C, Hein M, Brooks S, et al. Abuse potential of daridorexant, a dual orexin receptor antagonist: results from a randomised, double-blind, placebo-controlled crossover study. Journal of Clinical Pharmacology. 2022;62(10):1259-1271.
- Dauvilliers Y, Zammit G, Fietze I, et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Annals of Neurology. 2020;87(3):347-356.
- British National Formulary (BNF). Daridorexant — Drug monograph. National Institute for Health and Care Excellence (NICE). 2024.
- Idorsia Pharmaceuticals. QUVIVIQ (daridorexant) — Patient Information Leaflet (PIL). European version, last revised November 2024.
Editorial Team
This article has been written and medically reviewed by qualified healthcare professionals to ensure clinical accuracy and adherence to current international guidelines.
iMedic Medical Editorial Team
Specialists in pharmacology and sleep medicine with clinical and research experience in insomnia therapeutics and neuropharmacology.
iMedic Medical Review Board
Independent panel of board-certified physicians who verify all medical content against current EMA, FDA, and WHO guidelines.
All medical content on iMedic is based on peer-reviewed research and follows the GRADE evidence framework. We maintain strict editorial independence with no pharmaceutical company funding or advertising. Content is reviewed at least annually or when significant new evidence emerges. For more details, see our Editorial Standards.